The use of a 4.7 mg deslorelin slow release implant in male dogs in the field

Dedication

Dedicated to my dear “doctoral father” and mentor Prof. Dr. Dr. h.c. mult. Bostedt! Thank you for your faith in me and for your long-term support! – Meinem Doktorvater und Mentor Prof. Dr. Dr. h.c. mult. Bostedt gewidmet. Danke für Ihr Vertrauen in mich und Ihre langjährige Unterstützung! Sandra Goericke-Pesch

Abstract

Objective Slow-release GnRH agonist implants (SRI) are used for reversible medical downregulation of testicular function in male dogs as an alternative to surgery. The 4.7 mg deslorelin SRI should reduce testosterone after 6–8 weeks and induce castration-like effects for 6 months (mon). However, some individual variation is described in the field in regard to onset and duration of effect. For this reason, we aimed to study the effects of the 4.7 mg deslorelin SRI in a larger cohort.

Material and methods In total 50 intact, healthy male dogs (12–48 months, mon; 9–40 kg) were treated with a 4.7 mg deslorelin SRI into the umbilical area (TG, n=45) or served as untreated controls (CG, n=5). CG dogs were surgically castrated after measurement of testicular dimensions and blood sampling for testosterone. In TG, SRIs remained for 5 mon in place and subsequently 3–7 male dogs were surgically castrated at removal (week, W 0) or 1, 2, 3, 4, 5, 6, 7, 8 or 10 weeks later. Examination parameters were testicular dimensions (before treatment, at 4, 8, 12 W, 5 mon, weekly until castration), testosterone (before treatment, at 8 W, 5 mon, castration) and testicular histology (castration).

Results Whereas examination parameters did not differ between CG and TG before treatment, testicular volume and testosterone was significantly reduced at all time points during treatment. In all but 3 (8 W) and 2 male dogs (5 mon) testosterone was basal during treatment before removal, whereas the parameters were significantly reduced compared to pre-treatment in the respective dogs. After implant removal, testosterone and testicular volumes increased. However, different to earlier studies, the „restart“ was more variable with individual basal testosterone until W7, but also physiological testosterone concentrations in W2. Similarly, histological testicular findings at castration were quite variable: besides an arrest on spermatogonia and spermatocytes, elongated spermatids with normal spermatogenesis were found in individual dogs.

Conclusion Our study confirms the efficacy of the deslorelin SRI, but also individual variation especially regarding reversibility of effects on endocrine and germinative testicular function.

Clinical relevance Deslorelin SRIs offer a suitable alternative to surgical castration with individual variation to be considered when used in clinical practice.

Zusammenfassung

Gegenstand und Ziel Slow release GnRH-Agonist Implantate (SRI) werden bei Rüden zur reversiblen medikamentösen Downregulation der Hodenfunktion als Kastrationsalternative eingesetzt. Das 4,7 mg Deslorelin SRI soll nach spätestens 8 Wochen zu einer signifikanten Reduktion von Testosteron führen und ca. 6 Monate (Mon) wirken. Dennoch ist eine gewisse individuelle Variabilität bezüglich Wirkeintritt und -dauer im Praxisalltag beschrieben, weshalb es unser Ziel war, die Effekte in einer größeren Kohorte zu untersuchen.

Material und Methoden Hierzu wurden 50 intakte, gesunde Rüden im Alter von 12–48 Mon mit einem Gewicht von 9–40 kg entweder mit einem 4,7 mg Deslorelin SRI in die Nabelregion injiziert (n=45, TG) oder dienten als unbehandelte Kontrollen (n=5, CG). Die Hunde aus CG wurden nach Erfassung der Hodenmaße und Blutentnahme für Testosteron kastriert. In TG wurden die Implantate für 5 Mon belassen und dann jeweils 3–7 Rüden nach Entfernung (Woche, W0) oder 1, 2, 3, 4, 5, 6, 7, 8 oder 10 Wochen danach kastriert. Untersuchungsparameter waren Hodenmaße (Messung 4, 8, 12 W, 5 Mon, wöchentlich nach Entfernung bis Kastration), Testosteron (Blutprobe 8 W, 5 Mon, Kastration) und Hodenhistologie (Kastration).

Ergebnisse Während sich die Untersuchungsparameter vorher zwischen TG und CG nicht unterschieden, waren die Hodenvolumina und Testosteron infolge der Behandlung zu allen Terminen signifikant reduziert. Bei allen außer 3 Rüden nach 8 W und 2 Rüden nach 5 Mon war nach Behandlung Testosteron basal, wobei auch bei diesen zu anderen Zeitpunkten Testosteron und Hodenvolumina reduziert waren. Nach Implantatentfernung kam es zu einem Anstieg von Testosteron und Hodenvolumina. Im Vergleich zu vorherigen Studien verlief der „Restart“ allerdings deutlich variabler mit vereinzelten basalen Werten bis W7, aber auch physiologischen Testosteronkonzentrationen bereits in W2. Dementsprechend variabel stellten sich die histologischen Hodenbefunde zum Kastrationszeitpunkt dar, neben Arresten auf Ebene von Spermatogonien und Spermatozyten waren bei anderen Hunden elongierte Spermatiden mit weitgehend normaler Spermatogenese nachweisbar.

Schlussfolgerung Die Studie bestätigt die Wirksamkeit des Deslorelin SRIs, aber auch die individuelle Variabilität, v. a. hinsichtlich der Reversibilität der Effekte auf die endokrine und germinative Hodenfunktion.

Klinische Relevanz Deslorelin SRIs bieten eine geeignete Alternative zur chirurgischen Kastration, wobei die individuelle Variabilität in der Praxis unbedingt berücksichtigt werden muss.

Key words

Hormonal castration - GnRH agonist slow-release implant - downregulation - infertility

Schlüsselwörter

Hormonelle Kastration - slow release GnRH-Agonist Implantat - Downregulation - Infertilität

Publikationsverlauf

Eingereicht: 02. Mai 2023

Angenommen: 17. Juli 2023

Artikel online veröffentlicht:
11. Oktober 2023

• References

• 1 Rispoli LA, Nett TM. Pituitary gonadotropin-releasing hormone (GnRH) receptor: structure, distribution and regulation of expression. Anim Reprod Sci 2005; 88: 57-74 DOI: 10.1016/j.anireprosci.2005.05.004.
• 2 McArdle CA, Franklin J, Green L. et al. The gonadotrophin-releasing hormone receptor: signalling, cycling and desensitisation. Arch Physiol Biochem 2002; 110: 113-122 DOI: 10.1076/apab.110.1.113.893.
• 3 McArdle CA, Franklin J, Green L. et al. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 2002; 173: 1-11 DOI: 10.1677/joe.0.1730001.
• 4 Gregory SJ, Kaiser UB. Regulation of gonadotropins by inhibin and activin. Semin Reprod Med 2004; 22: 253-267 DOI: 10.1055/s-2004-831901.
• 5 Goericke-Pesch S, Spang A, Schulz M. et al. Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant. Reprod Dom Anim 2009; 44: 302-308 DOI: 10.1111/j.1439-0531.2009.01378.x.
• 6 Goericke-Pesch S. Long-term effects of GnRH agonists on fertility and behaviour. Reprod Domest Anim 2017; 52: 336-347 DOI: 10.1111/rda.12898.
• 7 Trigg TE, Doyle AG, Walsh JD. et al. A review of advances in the use of the GnRH agonist deslorelin in control of reproduction. Theriogenology 2006; 66: 1507-1512 DOI: 10.1016/j.theriogenology.2006.02.037.
• 8 Junaidi A, Williamson PE, Cummins JM. et al. Use of a new drug delivery formulation of the gonadotrophin-releasing hormone analogue Deslorelin for reversible long-term contraception in male dogs. Reprod Fertil Dev 2003; 15: 317-322 DOI: 10.1071/RD03039.
• 9 Junaidi A, Williamson PE, Martin GB. et al. Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, deslorelin. Reprod Domest Anim 2009; 44: 725-734 DOI: 10.1111/j.1439-0531.2008.01060.x.
• 10 Junaidi A, Williamson PE, Martin GB. et al. Pituitary and testicular endocrine responses to exogenous gonadotrophin-releasing hormone (GnRH) and luteinising hormone in male dogs treated with GnRH agonist implants. Reprod Fertil Dev 2007; 19: 891-898 DOI: 10.1071/rd07088.
• 11 Junaidi A, Williamson PE, Trigg TE. et al. Morphological study of the effects of the GnRH superagonist deslorelin on the canine testis and prostate gland. Reprod Domest Anim 2009; 44: 757-763 DOI: 10.1111/j.1439-0531.2008.01066.x.
• 12 Ludwig C, Desmoulins PO, Driancourt MA. et al. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant “Gonazon”; a preclinical trial. Theriogenology 2009; 71: 1037-1045 DOI: 10.1016/j.theriogenology.2008.10.015.
• 13 Goericke-Pesch S, Wilhelm E, Ludwig C. et al. Evaluation of the clinical efficacy of Gonazon implants in the treatment of reproductive pathologies, behavioral problems, and suppression of reproductive function in the male dog. Theriogenology 2010; 73: 920-926 DOI: 10.1016/j.theriogenology.2009.11.018.
• 14 Goericke-Pesch S, Ludwig C, Hoffmann B. Development of semen quality following reversible downregulation of testicular function in male dogs with a GnRH agonist implant. Reprod Domest Anim 2012; 47: 625-628 DOI: 10.1111/j.1439-0531.2011.01933.x.
• 15 Stempel S, Korber H, Reifarth L. et al. What Happens in Male Dogs after Treatment with a 4.7 mg Deslorelin Implant? II. Recovery of Testicular Function after Implant Removal. Animals (Basel) 2022; 12 DOI: 10.3390/ani12192545.
• 16 Stempel S, Korber H, Reifarth L. et al. What Happens in Male Dogs after Treatment with a 4.7 mg Deslorelin Implant? I. Flare up and Downregulation. Animals (Basel) 2022; 12 DOI: 10.3390/ani12182379.
• 17 Goericke-Pesch S, Wilhelm E, Hoffmann B. Hormonelle Downregulation der Hodenfunktion bei Rüde und Kater; eine retrospektive Studie. Prakt Tierarzt 2010; 91: 563-570
• 18 Riesenbeck A, Klein R. Hoffmann B. Downregulation, eine neue, reversible Möglichkeit zur Ausschaltung der Hodenfunktion beim Rüden. Prakt Tierarzt 2002; 83: 512-520
• 19 Trigg TE, Wright PJ, Armour AF. et al. Use of a GnRH analogue implant to produce reversible long-term suppression of reproductive function in male and female domestic dogs. J Reprod Fertil Suppl 2001; 57: 255-261
• 20 Stempel S, Goericke-Pesch S. [GnRH agonist implants in small animal practice - what do we know 13 years following EU registration?]. Tierarztl Prax Ausg K Kleintiere Heimtiere 2020; 48: 420-432 DOI: 10.1055/a-1274-9268.
• 21 Reichler IM. Gonadectomy in cats and dogs: a review of risks and benefits. Reprod Domest Anim 2009; 44: 29-35 DOI: 10.1111/j.1439-0531.2009.01437.x.
• 22 Hart LA, Hart BL. An Ancient Practice but a New Paradigm: Personal Choice for the Age to Spay or Neuter a Dog. Front Vet Sci 2021; 8: 603257 DOI: 10.3389/fvets.2021.603257.
• 23 Kutzler MA. Possible Relationship between Long-Term Adverse Health Effects of Gonad-Removing Surgical Sterilization and Luteinizing Hormone in Dogs. Animals (Basel) 2020; 10 DOI: 10.3390/ani10040599.
• 24 Arlt S, Wehrend A, Reichler IM. [Neutering of female dogs - old and new insights into Pros and Cons]. Tierarztl Prax Ausg K Kleintiere Heimtiere 2017; 45: 253-263 DOI: 10.15654/TPK-170322.
• 25 Gouletsou PG, Galatos AD, Leontides LS. Comparison between ultrasonographic and caliper measurements of testicular volume in the dog. Anim Reprod Sci 2008; 108: 1-12 DOI: 10.1016/j.anireprosci.2007.06.020.
• 26 Hoffmann B, Landeck A. Testicular endocrine function, seasonality and semen quality of the stallion. Anim Reprod Sci 1999; 57: 89-98 DOI: 10.1016/s0378-4320(99)00050-0.
• 27 DePalatis L, Moore J, Falvo RE. Plasma concentrations of testosterone and LH in the male dog. J Reprod Fertil 1978; 52: 201-207 DOI: 10.1530/jrf.0.0520201.
• 28 Nizanski W, Ochota M, Fontaine C. et al. B-Mode and Doppler Ultrasonographic Findings of Prostate Gland and Testes in Dogs Receiving Deslorelin Acetate or Osaterone Acetate. Animals (Basel) 2020; 10 DOI: 10.3390/ani10122379.
• 29 Polisca A, Orlandi R, Troisi A. et al. Clinical efficacy of the GnRH agonist (deslorelin) in dogs affected by benign prostatic hyperplasia and evaluation of prostatic blood flow by Doppler ultrasound. Reprod Domest Anim 2013; 48: 673-680 DOI: 10.1111/rda.12143.
• 30 Gentil M, Hoffmann B, Spang A. et al. Restart of steroidogenesis in dogs during recrudescence of testicular function following downregulation with a GnRH-agonist implant. Cell Tissue Res 2012; 350: 513-523 DOI: 10.1007/s00441-012-1506-5.
• 31 Goericke-Pesch S, Wehrend A. Determination of the alkaline phosphatase in canine seminalplasma to differentiate azoospermia and incomplete ejaculation (German). Tierärztl Prax 2008; 36: A24
• 32 Schafer-Somi S, Frohlich T, Schwendenwein I. Measurement of alkaline phosphatase in canine seminal plasma--an update. Reprod Domest Anim 2013; 48: e10-e12 DOI: 10.1111/j.1439-0531.2012.02025.x.